Results 281 to 290 of about 29,942,317 (406)
Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon. [PDF]
Roberts L, Barratt J.
europepmc +1 more source
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker +16 more
wiley +1 more source
Tumor-infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors. [PDF]
Li Z +5 more
europepmc +1 more source
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source
Not marginal but central: type I interferons unleash marginal zone B cells in Sjögren's disease. [PDF]
Werynski A +4 more
europepmc +1 more source
A brief history of T cell help to B cells
Shane Crotty
semanticscholar +1 more source
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande +11 more
wiley +1 more source
The Crosstalk Between B Cells and the Skeletal System During Development, Aging, and in Pathological Conditions. [PDF]
Terhaar H +9 more
europepmc +1 more source
RNF43 Inactivation Enhances the B‐RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells [PDF]
Shih‐Han Hsu +6 more
openalex +1 more source
Aggressive prostate cancer is associated with pericyte dysfunction
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source

